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What are White Matter Hyperintensities Made of?
Relevance to Vascular Cognitive Impairment
Joanna M. Wardlaw, MD, FRCR, FMedSci, FRSE; Maria C. Valdes Hernandez, BSc, PhD; Susana Mu~noz-Maniega, BSc, PhD
W hite matter hyperintensities (WMH) of presumedvascular origin, also referred to as leukoaraiosis, are
a very common finding on brain magnetic resonance imaging
(MRI) or computed tomography (CT) in older subjects and in
patients with stroke and dementia. They are associated with
cognitive impairment, triple the risk of stroke and double the
risk of dementia. Knowledge of their pathology derives mostly
from post mortem studies, many from some years ago. These,
by their nature, were generally small, sampled from selected
brain regions and probably reflect late-stage disease. They
focus on features of demyelination and axonal degeneration,
which may be easier to detect histopathologically than
changes in extracellular fluid. Here we review advances in
brain magnetic resonance imaging (MRI) that are revealing
white matter hyperintensities at earlier stages, and changes in
normal-appearing white matter that indicate tissue pathology,
less marked than those found in WMH. These “pre-visible”
changes show that altered interstitial fluid mobility and water
content, which may be reversible, probably predate demye-
lination and axonal damage, which are less likely to be
reversible and are probably a late-stage phenomenon. Neu-
roimaging is also revealing the dynamic nature of WMH, their
interactions with other pathological features such as second-
ary cortical and long tract damage, and contribution to
accumulating brain damage. These insights provide opportu-
nities to improve understanding the etiology and pathogenesis
of small vessel disease, and represents an enormous
unfinished agenda for preventing accumulation of brain
damage, and its associated cognitive and physical problems,
from mid to later life. Recognizing the earliest stages leading
to WMH development will provide important opportunities to
prevent (or even reverse) brain damage due to small vessel
disease at the earliest stages, and ameliorate its cognitive,
physical, stroke and dementia consequences.
Historical Perspective
Worldwide, about 15 million people have a stroke, from which 6
million die and 5 million are left permanently disabled each
year1; 35.6 million people worldwide are estimated to be living
with dementia, and this is expected to triple by 2050. Although
Alzheimer’s disease is the most commonly diagnosed form of
cognitive impairment in older people,2 cognitive impairment
due to vascular disease alone, or in addition to Alzheimer’s
disease, is very common and contributes to substantial
worsening of cognitive function for a given burden of Alzhei-
mer’s disease pathology.3 The most common form of vascular
cognitive impairment typically results in lesions visible on brain
scanning known collectively as small vessel disease (SVD) and
described in more detail below. Although stroke and dementia
are priorities for many governments, the cause of the 20% of
strokes and about 40% of dementias attributed to SVD4 remains
unclear, with limited options for prevention and treatment.
The finding of altered areas of white matter attenuation on
computed tomography (CT) was first brought to prominence in
the late 1980s by Hachinski and colleagues. They described
patchy low attenuation in the periventricular and deep white
matter, which they referred to as leukoaraiosis (Figure 1).5
These patchy white matter changes are more obvious as
abnormal areas of signal intensity on magnetic resonance
imaging (MRI) due to the latter’s better sensitivity to soft
tissue changes than CT, particularly for subtle alterations in
water content. The signal changes predominate in the
periventricular and deep white matter, so were commonly
referred to originally as “white matter lesions” although they
are also recognized to occur in the deep gray matter.6 These
areas are hyperintense on T2-weighted (T2), proton density-
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weighted (PD), and fluid attenuated inversion recovery (FLAIR)
MRI sequences, so are now by consensus referred to as
“white matter hyperintensities” (WMH), or “subcortical hyper-
intensities” where deep gray matter is also involved.6 They
are also hypointense on T1-weighted and hyperintense on
T2*-weighted sequences, but the most sensitive structural
sequence for visualizing WMH on MRI is generally the FLAIR
sequence (Figure 1).
MRI came into wider use in clinical practice and for
research in the late 1980s and early 1990s. Early MRI
B
C
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Figure 1. Examples of WMH on (A) CT, (B) MR FLAIR, (C and D) MR FLAIR and T2-weighted imaging. A,
Three adjacent CT images from 1 patient with severe WMH. B, Four different subjects showing, L to R,
normal to severe WMH. C, FLAIR and T2-w, same subject, show WMH and a lacune (arrow). D, top FLAIR,
bottom T2-w images showing that when subtle, WMH are more easily seen on FLAIR. CT indicates
computed tomography; FLAIR, fluid attenuated inversion recovery; MR, magnetic resonance; WMH, white
matter hyperintensities.
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scanners of the 1980s–1990s were generally of lower field
strength than are available routinely today. This affected their
sensitivity. For example, the earliest scanners in clinical use
were 0.2 or 0.5 Tesla field strength, and inevitably were less
sensitive to subtle tissue changes than are the 1.5 or 3 T MR
scanners that are in widespread use today. The early studies
also had fewer sequences available and these were less
sensitive to brain soft tissue changes than those available
now. For example, it was common to use T1-weighted (T1) or
T2 sequences, T1 being of similar sensitivity to subcortical
changes as is modern CT scanning, while T2 is relatively
insensitive to subtle white matter abnormalities and is less
good at identifying changes adjacent to a cerebrospinal
fluid (CSF)-containing space than is FLAIR (eg, in the
immediate periventricular tissues). Hence, when considering
imaging-pathological correlations, imaging-clinical, or imaging-
cognitive correlations, it is important to bear in mind that
early studies of MRI-pathology correlations may have lacked
sensitivity to detect the more subtle changes that are visible
today, and thus may have influenced our understanding of the
pathophysiology towards what are probably more established,
permanent changes.
WMH had been overlooked somewhat by pathologists up
until CT and MRI became available,7,8 much of the focus of
pathology examinations in the last century being on lacunes
(small CSF-containing cavities)9,10 that are easier to detect
pathologically than subtle WMH.11,12 The diffuse and often
subtle changes of WMH may be hard to see macroscopically
on brain sections until they are advanced13; when subtle, the
full extent of WMH may be difficult to appreciate histologically
unless specifically sought in aging-related changes14 or in
other white matter diseases such as multiple sclerosis.15 In
contrast, lacunes, ie, small CSF-containing cavities, are more
obvious pathologically and had been described in numerous
detailed pathology studies (summarized in Bailey et al16)
although there were not many imaging-pathology correlations
for lacunes either.
Clinical Importance
Until relatively recently, WMH were generally dismissed as
inevitable consequences of “normal” advancing age. This is
clearly not true. Although WMH do become more common
with advancing age,17 their prevalence is highly variable.
Furthermore, numerous studies indicate that they have
important clinical and risk factor associations, emphasizing
that they should not simply be overlooked as inevitable
“silent” consequences of the aging brain.
In a meta-analysis of 22 longitudinal studies, WMH were
clearly associated with progressive cognitive impairment, a
2-fold increase in the risk of dementia and a 3-fold increase in
risk of stroke.18 WMH also affect physical function, resulting
in abnormal gait19 and disturbed balance.20 WMH increase
the risk of late onset depression.21 Furthermore, WMH are
highly heritable,22 and they vary with familial longevity being
less frequent in subjects with long-lived parents.23 WMH are
inversely associated with intelligence in youth,24 and with
educational attainment.25 Whether these latter associations
indicate relationships between intelligence and risk factor
exposure or reflect brain resilience to damage,26 are as yet
unknown.
The prevalence of WMH increases with increasing vascular
risk factors, including hypertension,27–29 diabetes,30 smok-
ing,31,32 as well as with many other as yet undetermined risk
factors.33 Risk factor exposure seems to be particularly
important if it occurs in middle age,29,34 but the relative
importance of different risk factors may also vary in different
age groups. A large multicenter study of WMH in 2699 stroke
patients in 11 stroke centers in Korea suggested that raised
cholesterol was a more important risk factor for WMH in older
hypertensive patients whereas age alone was the major risk
factor in older non-hypertensive patients. Diabetesmellitus was
an important risk factor in younger non-hypertensives.35 It is
unclear as yet if hypertension has most of its effect directly on
the brain, or if it results in systemic vascular stiffening, which in
turn affects the brain white matter36,37 and cognition.38
Accumulating evidence, including associations with left ven-
tricular hypertrophy, tend to point to the former explana-
tion,35,37 but more longitudinal studies to determine the
sequence of development of WMH in relation to risk factors
are required. Additionally, there are as yet mixed results from
randomized trials on whether risk factor reduction can prevent
WMH progression or cognitive decline in older subjects,39–41
and some evidence that too aggressive blood pressure reduc-
tion in old age could actually worsenwhitematter damage42 and
cognitive decline, perhaps if autoregulation is impaired through
vessel stiffening and loss of vasoreactivity. Further trials of risk
factor management are needed and specifically at different
ages because different vascular risk factors may have more
impact at different ages (eg, hypertension in middle age,
cholesterol at older ages35). Physical activity is suggested to
protect against WMH in cross-sectional studies,43–45 but
whether exercise can prevent progression or development of
WMH remains to be tested in randomized clinical trials.
WMH are part of the spectrum of small vessel disease
(SVD) which includes lacunar (or small subcortical) ischemic
and hemorrhagic stroke, lacunes, microbleeds, perivascular
spaces and brain atrophy (Figure 2).6,46 All of these features,
individually, are associated with cognitive impairment,47–51
even when subtle.
The dynamic nature of these inter-related lesions is
illustrated by studying patterns of lesion evolution (Figure 3):
acute small subcortical infarcts can disappear (10%), remain
looking like a WMH (60% to 70%), or cavitate to form a lacune
DOI: 10.1161/JAHA.114.001140 Journal of the American Heart Association 3
WMH and VCI Wardlaw et al
B
A
S
IC
S
C
IE
N
C
E
F
O
R
C
L
IN
IC
IA
N
S
(20% to 30%)52–54; lacunes may form at the edge55 or (in our
experience) in the middle of a WMH; WMH can “grow” at the
edges of small subcortical infarcts56; incident lacunes57 and
WMH58 are associated with cortical thinning and cerebral
atrophy59; all of which indicate progressive and accumulating
brain damage. Furthermore, WMH increase risk of brain
damage in the presence of other pathologies, for example,
they associate with infarct growth and worse outcome after
large artery stroke,60,61 and they predict poor functional
stroke outcome.62–64
The effects of all these SVD features on cognition are
cumulative,65 (in submission) providing further indication that
together these SVD features are closely related pathologi-
cally,52 and represent cumulative brain damage,32 the
prevention of which should help ameliorate brain tissue
damage, reduce loss of normal brain cognitive and physical
function and preserve independent survival in old age.43
What Do Pathology Studies Suggest That
WMH Are Due To?
Pathology studies are, unfortunately, infrequent12,66,67 com-
pared with the number of WMH captured in imaging studies.
There are particularly few pathology studies that have linked
individual lesions seen on MRI with their pathological
examination.12,68,69 Pathology studies have been hampered
by difficulty in matching up individual small lesions on imaging
with their pathological counterpart,11,68 with limitations of
sampling,13 of fixation,70 of definitions,71–73 they provide
“snapshots” of disease evolution, and because end-stage
damage may obliterate the earliest stages of disease.
As described above, the earlier pathology reports focused
on demyelination and axonal loss in WMH7 and described the
changes as “ischemic”.74,75 Demyelination and axonal
destruction imply that the changes are permanent. Indeed,
Figure 2. STRIVE examples of different features of small vessel disease, including white matter hyperintensities. Reproduced with permission
from Wardlaw et al.6 DWI indicates diffusion-weighted imaging; FLAIR, fluid attenuated inversion recovery; GRE, gradient recalled echo; STRIVE,
standards for reporting vascular changes on neuroimaging; SWI, susceptibility-weighted imaging.
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extensive WMH were associated with reduced density of glia
and vacuolation.8 More subtle WMH on MRI were associated
with microglial and endothelial activation.13 Some studies
differentiate periventricular from deep WMH12,76,77 although
imaging studies indicate that periventricular and deep WMH
are probably mostly part of a continuous pathology.76,78 A
recent very large study in 2699 patients with stroke from 11
stroke centers in Korea created statistical maps of WMH
distribution and provided more evidence to support treating
periventricular and deep WMH as a continuous pathology, any
apparent difference in distribution in some patients simply
reflecting an earlier stage in disease.35 Notwithstanding, the
available pathology describes periventricular WMH as having
discontinuous ependyma, gliosis, loosening of the white
matter fibers, and myelin loss around tortuous venules in
perivascular spaces,11,12,79 the gliosis, demyelination, and
fiber loss worsening as the periventricular WMH worsened. In
deep WMH, there was demyelination, gliosis, and axonal loss
around perivascular spaces, with vacuolation and increased
tissue loss as the lesions became more severe.12 The changes
were heterogenous.77 WMH in patients with AD showed more
microglial activation than in WMH of age-matched controls.80
The variation in pathological severity might help explain some
of the variation in the association between WMH severity and
cognitive change in old age80 although this needs to be
verified in larger and more heterogeneous populations with
good cognitive, dementia and SVD phenotyping.
Some reports indicate the presence of proteins in the
perivascular tissues in human WMH81 and suggest that the
arteriolar wall thickening seen in SVD is also a consequence
of the movement of plasma proteins into the vessel walls.82
The proteins include fibrinogen, immunoglobulins, thrombo-
modulin,83 and occur in subcortical grey and white matter and
are also seen in normal appearing white matter and are
associated with microglia.81 The microglia and proteins were
more frequent in areas of WMH with more advanced tissue
loss.81 Increased albumin was found in the interstitial tissues
of brains of older subjects with WMH84 although it was
uncertain as to where the albumin had come from in this
study as the endothelial tight junction proteins were said to
be intact. Others have not identified direct evidence of blood-
brain barrier (BBB) impairment despite identifying proteins
associated with endothelial activation83 and that had extrav-
asated into the perivascular tissues.85 However, the cerebral
blood flow and the cerebrovascular endothelial surface area
are both so large that there would not have to be much
Thinning of 
overlying 
cortex
Acute small subcortical 
infarct (white), may 
evolve to: a) cavitate and 
shrink (grey) or about 
10% can disappear; 
b) develop a WMH ‘cap’ 
(yellow), c) project its 
effects onto the overlying 
cortex causing thinning 
(blue) and to d) the 
inferior projection fibres to 
the brainstem and spinal 
cord. 
Periventricular and deep 
WMH (pale yellow) can 
increase in size (dotted 
yellow), occasionally 
shrink, and lead to 
atrophy of white matter 
(inset, lower image) and 
overlying cortex (blue).
Thinning of 
overlying 
cortex
Figure 3. Diagram of dynamic mechanisms by which WMH and SVD lead to brain damage. SVD indicates
small vessel disease; WMH, white matter hyperintensities.
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breach of the BBB for proteins and fluid to accumulate in the
interstitial spaces. It is likely also that such tissue fluid shifts
are difficult to identify pathologically or overlooked as fixation
artifact, where fixation methods involve freezing or dehydra-
tion, which may affect tissue content.70
Numerous in vivo studies have found raised CSF:plasma
albumin ratios with advancing age, in patients with Alzhei-
mer’s disease, in vascular dementia, and in patients with
WMH,86 and suggested a role for chronic brain edema in
forming WMH and more advanced damage in the form of
lacunes.87–89 Undoubtedly the pathological picture is mixed
and complex90: despite the risk factor association, immuno-
histochemical and gene expression microarray studies sug-
gesting a role for ischemia, hypoxia, or hypoperfusion, studies
also show immune activation, BBB dysfunction, altered cell
metabolic pathways, and glial injury.90 The abnormalities are
now being recognized in normal-appearing white matter as
well as in WMH. Therefore, regardless of where the albumin or
other plasma proteins came from, or how they got into the
interstitial tissues, there does appear to be a role for loss of
normal BBB function and fluid shifts into the brain leading to
secondary brain damage91,92; if arrested or reversed early, the
interstitial fluid shifts may be more reversible than demyelin-
ation and axonal loss.
What Does Imaging Suggest?
To understand more about the pathophysiology of WMH, we
must turn to imaging methods that allow us to detect and
quantify subvisible tissue changes on a per voxel basis in vivo.
Structural changes in the integrity of the brain’s white matter
are commonly observed through MRI methods such as
diffusion tensor imaging (DTI), a widely available imaging
technique that provides quantitative measures of the mobility
of water molecules in vivo. Parameters obtained from the
water diffusion tensor are used as diagnostic markers for
clinical applications. The most commonly used are fractional
anisotropy (FA), which indicates the deviation from pure
isotropic diffusion of water mobility in vivo, and mean
diffusivity (MD), which measures the magnitude of diffusion
of the water molecules.93 Both the magnitude and direction-
ality of the water diffusion are affected by the underlying
tissue architecture and can demonstrate, for example,
alterations in axonal microstructure or interstitial fluid.94–98
Further potential MRI biomarkers of white matter damage
are the magnetization transfer ratio (MTR) and the longitudinal
relaxation time (T1). MTR is obtained from magnetization
transfer MRI99 and can show pathological changes in the
white matter structure that involve macromolecules in the cell
membrane, such as inflammation or demyelination.100 T1
relaxation time is a weighted average of the free and bound
water phases101 providing quantitative information on brain
water content, and is therefore a potential marker for
edematous brain tissue.94
Other methods of assessing alterations in normal brain
tissue function use dynamic imaging following intravenous
injection of a contrast agent. In dynamic contrast-enhanced
MRI102 a series of T1-weighted images are acquired dynam-
ically after injection, enabling the measurement of BBB
permeability.103,104 Similarly, dynamic susceptibility contrast
MRI is used to measure cerebral perfusion and estimate
regional cerebral blood volume and cerebral blood flow (CBF),
again by tracking a contrast agent bolus using a T2*-weighted
sequence.105,106
The measurement of these MR imaging biomarkers in
addition to structural “visible” brain changes, can help to
identify the pathophysiological changes within normal-appear-
ing white matter and WMH in vivo and inform our under-
standing of their pathophysiology.
Studies in humans have shown that MD and T1 increase
while FA and MTR decrease significantly in areas of WMH
when compared to normal appearing white matter,98,107–109
indicating pathological processes involving increased water
content and mobility, demyelination, and axonal loss. MD was
reported as the parameter that discriminated best between
normal-appearing white matter and WMH (Figure 4).109
Perfusion MRI studies also showed decreased CBF in regions
of WMH,110,111 although it remains uncertain as to how much
the blood flow reduction represents reduced flow due to
having less tissue to supply but is not the primary cause of the
damage,37,112 or is the primary cause of worsening of tissue
damage:113,114 there is some evidence for both explana-
tions.115 The dynamics of WMH progression and associations
with CBF are complex and regionally specific.116
Imaging demonstrates that WMH are heterogeneous, ie,
they represent different amounts of tissue damage, as
reflected in their degree of “whiteness” and in features seen
on more recent MR scanners such as “dirty white matter”
(Figure 5). Moreover, studies using MTR show that MTR
differs between frontal and occipital WMH,117 either indicat-
ing different stages of tissue damage or possibly different
underlying tissue constructs.
The relationships between different parameters observed
in WMH differed from those relationships in normal-appearing
white matter (Figure 6). Significant correlations appeared
between MTR and both FA and MD in WMH, whereas these
parameters were not correlated in normal-appearing white
matter, indicating that cellular breakdown in WMH allows
quantitative MRI parameters to take a much wider range of
values than in healthy tissue, where they are kept within tight
bounds and are likely to be independent.98
Several reports indicate that the tissue structural and vascular
changes spread further than the visible area of the WMH,
rather than being confined to the visible WMH109,111,118-120
DOI: 10.1161/JAHA.114.001140 Journal of the American Heart Association 6
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Figure 4. Images for FA, MD, T1, and MTR and corresponding values in normal-appearing white matter
and WMH. And corresponding ROC curves for each parameter’s ability to differentiate normal white matter
from WMH. MD shows a near perfect ROC curve. Top 2 images show the original FLAIR image and the
tissue segmentation into normal white matter and WMH. FA indicates fractional anisotropy; FLAIR, fluid
attenuated inversion recovery; MD, mean diffusivity; MTR, magnetisation transfer ratio; NAWM, normal-
appearing white matter; ROC, receiver operator characteristic; WMH, white matter hyperintensities.
DOI: 10.1161/JAHA.114.001140 Journal of the American Heart Association 7
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consistent with recent pathological reports.90 The changes
radiate into normal-appearing white matter, particularly in the
immediate peri-WMH tissue, indicating that the underlying
pathology is a diffuse process affecting much of the white
matter and even other parts of the brain, and that visible lesions,
ie, the WMH, are probably only the “tip of the iceberg.”
This compromised normal-appearing white matter integrity
in the presence of WMH has been observed through different
quantitative imaging techniques. For example, CBF121 and
cerebrovascular reactivity were reduced and BBB permeability
was increased in the normal appearing white matter of
healthy elderly subjects and all were associated with the
presence of WMH.122 BBB permeability increases with
advancing age during normal aging, but is further increased
in dementia particularly in patients with vascular dementia
and in patients with WMH.86 Others have found increases in
A B C D
Figure 5. FLAIR image through the lateral ventricles showing severe (ie, intense) WMH and less-intense white matter damage (A), represented
in blue and red, respectively in (B) and which correspond with the intensities arrowed in the histogram (C). Less-intense damage can be also
observed in the T1-weighted modality as the yellow arrows show (D). FLAIR indicates fluid-attenuation inversion recovery; WMH, white matter
hyperintensities.
Figure 6. Correlations between FA, MTR, MD and T1 in NAWM and WMH. In general, the T1 and FA, MD
and MTR show stronger correlations in WMH than in NAWM. FA indicates fractional anisotropy; MD, mean
diffusivity; MTR, magnetization transfer ratio; NAWM, normal-appearing white matter; WMH, white matter
hyperintensities.
DOI: 10.1161/JAHA.114.001140 Journal of the American Heart Association 8
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BBB permeability in NAWM in patients with WMH,123 in
patients with lacunar versus cortical ischemic stroke, with
increasing age and numbers of enlarged perivascular
spaces,124 and in WHM in vascular dementia.125 The MD
and FA of NAWM have been also associated with WMH
volume.120,126–128
However, studies typically include subjects of widely varying
age and the changes observed in NAWM integrity relative to
WMH load could also be a consequence of the older age of
those subjects with more WMH.17,129,130 A more recent study
in a large cohort of older people of near-homogeneous age
reported that FA, MD, MTR, and T1 were all associated with the
severity of WMH (highest Fazekas scores) – even after
accounting for age, gender, exposure to common vascular risk
factors and the proximity to WMH – proving that the changes
observed were not just a function of age.109 Moreover,
although all 4 parameters measured in NAWM were related
to WMH severity in those with most WMH, only the MD of
NAWM showed changes within the mildest range of WMH.
Additionally, of the 4 quantitative parameters of MD, FA, MTR
and T1, it was MD that showed the best differentiation of WMH
from normal-appearing white matter, performing substantially
better on received operator characteristic (ROC) curves than
did FA, MTR, or T1. This combination of findings suggests that
the earliest pathological processes responsible for WMH
involve changes in interstitial fluid mobility.109
Although observed by others,98 the concept of “WMH
penumbra” was introduced by Maillard et al118 after they
observed that the effects on FA are not only globally
influenced by the WMH load, but also locally influenced by
the distance into normal-appearing white matter from the
edge of the WMH. This idea of the more abnormal the tissue,
the closer the proximity to the WMH, was recently corrobo-
rated by measuring MRI quantitative parameters in the
normal-appearing white matter in “contours” set at increasing
distance from the visible edge of the WMH on FLAIR. In this
contour-based analysis, MD decreased and MTR increased
with increasing distance from the WMH over all distances
assessed, whereas FA and T1 mainly showed only slight
changes in the closest contours to the WMH (Figure 7).109
Longitudinal studies suggest that people with lower white
matter integrity at baseline are more likely to progress to
cognitive impairment or frank Alzheimer’s disease than are
those with higher white matter integrity.131 Having a high
WMH burden increases the risk of worsening WMH several
years later,132 as well as of stroke, dementia, and death.18
New lacunes form at the edges of WMH55 and WMH form at
the edges of small subcortical infarcts or lacunes,56 ie,
damage begets damage (Figure 3).
The precise sequence of pathologic processes underpin-
ning the microstructural changes in white matter integrity
within and around WMH are yet to be fully described.
Pathology studies have described rarefaction, demyelination,
and axonal loss in WMH as outlined above, which are
compatible with the observed increases in MD and T1, and the
decreases in FA, MTR, and CBF detected using neuroimaging.
Some changes such as minor fluxes in fluid content may be
relatively easier to detect with MR imaging, which is highly
sensitive to water shifts. Hence, neuroimaging in vivo is highly
complementary to pathology by providing tools to aid the
identification of the earliest stages in the pathological
processes that end in the development of visible WMH.46
The increase in MD in NAWM seen even in the presence of the
mildest WMH burden, and the fact that this parameter also
provides excellent discrimination between both tissue types
on ROC curves, suggests that altered mobility of interstitial
fluid occurs earlier in the developing pathology of WMH in the
aging brain than do changes in myelin (MTR), axonal integrity
(FA), or total water content (T1). However, further work
relating these imaging biomarkers to histopathological find-
ings, especially at early stages in disease, and in longitudinal
studies, is required to understand fully the pathological
processes that are responsible for white matter damage
within and around the WMH.
Limitations of Imaging Approaches to
Determining WMH Pathophysiology
MRI processing methods for WMH detection and differenti-
ation from artifacts, co-registration of different types of
images, and image processing methods such as bias field
correction, affect measurements of lesions and brain tissue
parameters. The full analysis of these limitations is beyond
the remit of this paper, but these limitations are important but
rarely mentioned in imaging papers so are discussed briefly
here for completeness. Indeed the full scope of the effects of
these limitations is only just beginning to be understood by
the clinical research community.
Methods to quantify WMH volume are evolving rapidly.
Many were developed for use in one study, reflect the
particular subject, image acquisition characteristics and WMH
burden of that study population. Few, if any, are in use in
clinical practice. Many research groups develop their scanning
protocol and WMH segmentation approach and apply it to
subsequent studies, without further validation. The protocol
may not be changed or improved partly due to lack of
availability of source codes and/or software and because of a
natural desire to minimize the effect of protocol changes on
measured variables. Most studies use a semi-automatic
thresholding approach to identify WMH on FLAIR images.
These threshold selection methods may then be applied in
different studies assuming that the reliability will not change,
which is unlikely to be correct as FLAIR images are not
quantitative and the signal to noise ratio may not be the
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Figure 7. Effect on MD, FA, MTR, and T1 of increasing burden of WMH, in the WMH and at
2 mmdistance increments from theWMH edge into the NAWM (2 mm-NAWMrem). Top left,
illustratesWMH (red) and contours (different color bands), right, 1 to 6,WMHFazekas scores.
Lower left graphs show change in the 4MR parameters fromWMHand at increasing distance
into the NAWM; lower right graphs show the parameter changes at increasing distance into
NAWMsplit by totalWMHburden (Fazekas score). Adapted fromMu~noz-Maniega et al.109 FA
indicates fractional anisotropy; MD, mean diffusivity; MTR, magnetisation transfer ratio;
NAWM, normal-appearing white matter; WMH, white matter hyperintensities.
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same. Thresholding on a single image such as FLAIR requires
individualized thresholds (“one size” does not “fit all cases”);
multispectral approaches using several sequences combined
are more accurate.133 A full description of the WMH volume
measurement methods used in different studies to date is
beyond the scope of this paper but is available upon request.
WMH volume measurement is time consuming, hence
larger studies seek automated approaches but it is not known
whether all studies check each case individually for the
accuracy of segmentation, or the rigor with which this is
performed where done. However, there is as yet no
automated approach that can identify WMH accurately
without any human input – all require visual assessment
and manual correction, particularly in populations with
advanced age or stroke where the brains are more likely to
be abnormal (Figure 8) and features of similar signal charac-
teristics like stroke lesions, if not excluded, will distort the
WMH volume measurements with subsequent alterations on
the outcome of the study.134
Artifacts that mimic WMH (to a computer algorithm) are
numerous (Table) and require manual editing.135,136 Guidelines
exist to differentiate WMH from artifacts,135,137 but these lack
uniformity and consensus. Some class periventricular hyper-
intense thin lines around the lateral ventricles as artifact,135,139
but others found a high correlation between signal intensity
levels and width of the periventricular WMH, total WMH
volumes, periventricular WMH severity, vascular risk factors,
and stroke,76 indicating that periventricular WMH are true
tissue abnormalities and should not be considered artifacts.78
Differentiating WMH from other SVD lesions such as
perivascular spaces6,8,150 and lacunes6 may be difficult.
Differences in magnet strengths can lead to inconsistent
assessment of WMH, eg, subtle tissue changes in normal-
appearing white matter could go unnoticed at 3 T due to
noise151,152 or vice versa (Figure 9).153 Reported mean intra-
and inter-scanner coefficients of variation in automatic
volumetric measurements of brain structures range from
0.87% to 15.1% (median 4.80%). Only limited information is
available for the range of values for direct comparisons of
WMH assessed at 1.5 and 3 T.153,154
Image registration methods impose limitations, eg, native
versus standard space, atlases, and registering structural to
DTI or other echoplanar images, all can distort lesion location
and size. In one study of recent small subcortical infarcts of
<1.5 cm diameter, we found that the volume of some acute
lesions was more than doubled if measured after registering
the image in standard space against a routinely available
atlas, rather than performing the measurement in native
space (ie, on the patient’s own brain scan) prior to registra-
tion. Mapping the images of interest against brain atlases
allows analysis of lesion distribution (eg, lobar distribution,
vascular territories, etc), but relies on accurate registration of
a brain template to the brains of the subjects in the
population of interest. While state-of-art non-linear registra-
tion methods155 have demonstrated very good performance,
these have yet to be tested in SVD or aging studies. This is
important as it may influence perceived lesion or tract
location and represents a complex challenge that needs to be
addressed. In general, atlases should be used that are as
representative as possible of the age range and population of
interest. Unfortunately, no atlases as yet include structures
that are typically affected by WMH, such as the major arterial
“borderzones,”156 but variation in vascular territories may
account for some variation in WMH burden.157
A B C D
Figure 8. Some factors which confound the delineation of WMH. FLAIR axial images from a patient 4 days after a stroke (A) and a year later
(B): while the boundary of the periventricular WMH can be well perceived on the baseline scan, it coalesces with the large infarct after a year
(yellow arrow) making it impossible to quantitatively determine accurately the increase in the stroke lesion separated from the increase in the
WMH. Different patient (C) has a recent small subcortical stroke lesion arrowed in yellow, and artifacts arrowed in blue; (D) a lacune (yellow
arrow) confluent with the periventricular WMH, real thalamic hyperintensity arrowed in magenta and thalamic artifact arrowed in blue create
difficulties for measuring the WMH. FLAIR indicates fluid attenuation inversion recovery; WMH, white matter hyperintensities.
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Irrespective of the method used to quantify WMH, one
factor that affects the assessment of WMH is the subtle
variation in the radio-frequency magnetic field known as
magnetic field inhomogeneity. Image processing methods
that correct for magnetic field inhomogeneities have been
used in some studies.158–162 Some of these methods are
scanner and protocol-specific159,162 while others are part of
publicly available software where the algorithms assume that
the software is applied to brain images with only voxels
containing CSF, gray matter, and white matter, after all other
tissue types are removed (http://brainsuite.org/processing/
surfaceextraction/bfc/, http://bioimagesuite.yale.edu/man-
ual/guide/correction.aspx). If applied to FLAIR images with
WMH, these tools may try to remove the WMH or focal
infarcts, which are interpreted as inhomogeneities (Fig-
ure 10). Hence, these methods should be avoided until it is
clear that they do not simply remove the WMH or alter their
apparent distribution.
Two final features of WMH that have been overlooked to
date are (1) the presence of ill-defined subtle hyperintense
white matter that are non-continuous and diffuse, with varying
erratic intensity patterns emerging from the lateral ventricle
walls, sometimes known as “dirty white matter”163 and which
may be an indicator of pre-lesional changes (Figure 5); and (2)
the fact that WMH can get smaller or disappear rather than
continuously enlarging (Figure 11). “Dirty white matter” is
probably a real feature indicating subtle tissue damage, as
suggested by the signal change in Figure 5. It will influence
where the boundary of the WMH is set and hence associations
with other MR parameters like FA and MD.
That WMH can reduce or disappear should not be a
surprise if we accept that much of the signal change on FLAIR
or T2 is due to shifts in water content and not just permanent
myelin loss or axonal damage. WMH regression was noted in
only one previous published case.164 Most longitudinal
studies report “no change” or “progression” of WMH. Three
Table. Common Artifacts That Confound the Identification of WMH on FLAIR MRI
Artifact Type Artifact Location Characteristic Effect References
CSF flow Fourth ventricle, aqueduct,
cistern ventral
to mesencephalon
Hyperintense tissue surrounding these structures;
periventricular hyperintensity with constant
gradient
136,138–145
CSF flow Bilateral sylvian fissures and
insular cortex
Uniform hyperintensity along the external capsule 136,146,147
CSF flow Third ventricle and Fornix Hyperintense tissue surrounding the third ventricle
and fornix; diffuse periventricular hyperintensity
gradually decereasing in strength towards the
antero-medial thalamic nucleus and internal
capsule
136,140,142,144,147
CSF flow Lateral ventricles Hyperintense cluster near the walls of the anterior
horns of the lateral ventricles
136, 140,142, 144,147
CSF flow Choroid plexus Small hyperintense cluster above the temporal
horns of the lateral ventricles
144
Corticospinal tract Pathways of the corticospinal
tracts
Bilateral and symmetric hyperintensities with
similar signal level in the junction between the
internal capsule and the medial thalamic nucleus
147
Magnetic field susceptibility Amygdaloid nucleus and anterior
temporal poles
Wide hyperintense clusters covering the amygdaloid
nuclus and the anterior temporal poles
136,145,148
Magnetic field susceptibility
and CSF flow
Cingulate gyrus Hyperintense tissue along the longitudinal cerebral
fissure on the anterior section and on the territory
of the anterior cerebral artery
136
Patient motion (eye movement) Around the eyes Ghosting effect on tissue around the eyes 136,143
Patient motion (Head movement) Throughout the whole image Concentric hyperintense rings that distort/mask real
WMH
136,138,148,149
Image reconstruction (Gibbs
ringing)
Throughout the brain accentuated near
the skull borders
Concentric hyperintense rings that follow signal
intensity borders and distort/mask small WMH
145
Blood flow Near the sinuses and main arteries Small linear hyperintensities near the sinuses and
carotid arteries
145
Note, only publications that were dedicated to analyse and describe these artifacts on FLAIR MRI and/or propose methods to compensate them are referenced. CSF indicates
cerebrospinal fluid; FLAIR, Fluid Attenuated Inversion Recovery; MRI, magnetic resonance imaging; WMH, white matter hyperintensities.
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studies mentioned “minor regression” in some patients, but
classified these as “no progression” without further explora-
tion,165 attributed reductions in WMH volume to measure-
ment variability,166 or reported (small) negative volume
changes without comment.167 We have noted reductions in
WMH volume as well as increases, eg, about a third of 200
patients who presented with minor stroke had a small
reduction in WMH volume on repeat MRI a year after stroke
(in submission). In a few cases, the changes were more
obvious (Figure 11). The reasons for reduction in WMH are
unclear but might relate to improved vascular risk factor
control. If some WMH are areas of tissue edema, then
reduction in tissue edema would both reduce WMH and
decrease brain volume. Indeed, in patients with CADASIL new
WMH were associated with subtle increased brain volume.168
Finally, fluctuations in WMH and white matter subvisible
damage might account for the return to normal cognition seen
in a few studies in patients with mild cognitive impairment.2
Although these fluctuations have been attributed to recovery
from depression, delirium, heart failure, or autoimmune
disorders, the improving cognition could equally be attributed
to resolution of transient fluid-related white matter damage
before permanent axonal injury or demyelination has
occurred.
Implications for Clinical Practice
There is strong evidence that WMH are clinically important
markers of increased risk of stroke, dementia, death, depres-
sion, impaired gait, and mobility, in cross-sectional and in
longitudinal studies. They associate with brain damage such
as global atrophy59 and other features of small vessel brain
damage,32 with focal progressive visible brain damage,55,57
are markers of underlying subvisible diffuse brain
A B C
Figure 9. Three different patients, but with similar amounts of WMH, scanned with slightly different slice
thicknesses and at 1.5 or 3 T, illustrate the resulting differences in signal of WMH and normal tissues and
hence the need for changes in tissue and WMH volume measurement methods. Slice thickness 1 mm2 (A),
0.479 mm2 (B), and 1 mm2 (C) and MR scanner field strength—1.5 T (A and B) and 3 T (C) affect image
appearance. Alterations in imaging parameters influence the image appearance and hence the performance
of any software used to measure the WMH as all software ultimately rely on differences in signal
characteristics between the tissue and lesions of interest. MR indicates magnetic resonance; WMH, white
matter hyperintensities.
Original Bias corrected
Figure 10. Effect of incautious use of bias field correction on
cortical infarct and WMH. The left image shows the original MR
FLAIR image with a right frontal cortical infarct (arrow) and
numerous WMH. Following bias field correction (left) the frontal
infarct appears much smaller, some of the WMH have become
more (eg, posterior areas) and some now appear split into smaller
components (mid centrum semiovale) as the bias field smoothing
software tries to “even out” the distribution of signal intensities
across the image. FLAIR indicates fluid attenuation inversion
recovery; MR, magnetic resonance; WMH, white matter hyperin-
tensities.
DOI: 10.1161/JAHA.114.001140 Journal of the American Heart Association 13
WMH and VCI Wardlaw et al
B
A
S
IC
S
C
IE
N
C
E
F
O
R
C
L
IN
IC
IA
N
S
damage,19,98,109,119 and predict infarct growth and worse
outcome after large artery stroke.60,61 They could be consid-
ered as the neuroimaging marker of “brain frailty.”169
However, they should not be viewed only as “untreatable”
or “permanent”: in vivo imaging indicates that water shifts
and water content are prominent and represent early
changes in WMH. Given the associations of WMH with
traditional vascular risk factors, it is reasonable to manage
risk factors according to current guidelines until further data
from randomized controlled trials are available. Future trials
should assess the effect of risk factor reduction by age group
because common vascular risk factors may act differently at
different ages. For example, blood pressure reduction in older
people may need to work to less stringent target levels than
in younger people because some older people with less
reactive vasculature may become more dependent on blood
pressure for cerebral perfusion than in subjects whose
vasculature retains its elasticity and responsiveness. Simi-
larly, cholesterol reduction may be relatively more important
in older people to protect the brain than in younger people
where its main action may be on the heart. These specula-
tions are based on emerging observations (eg, and the
PODCAST trial, paper in preparation) and require careful
testing in future trials.
Given the lack of readily available computational analysis
methods, and the simplicity and durability of deriving visual
WMH scores,170 it is reasonable to use visual scores in clinical
practice – at least these would provide some more precise
quantification than purely descriptive reports. The addition of
imaging methods such as DTI to routine clinical assessment
of patients with minor stroke, cognitive, or aging would
facilitate quantification of mean diffusivity or fractional
anisotropy in normal-appearing white matter to indicate
subvisible brain damage.
Implications for Research
Research should target the enormous unfinished agenda that
constitutes brain damage represented by WMH and diffuse
small vessel disease. There should be more imaging-
Figure 11. Example of disappearing white matter hyperintensities. Left, scan at presentation with small
subcortical infarct. Right, scan 1 year later. Inset image is diffusion image from original presentation
showing small subcortical infarct that precipitated medical consultation. The images were obtained on the
same scanner, using the same sequence with careful quality assurance maintained throughout. Note the
lesions have become smaller and less white at 1 year compared with presentation.
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neuropathology analyses of individual lesions in humans and
in relevant experimental models. There should be more
awareness that WMH are heterogeneous, can diminish as well
as increase, that they represent a tip of the iceberg in terms
of damage to the brain and lead to progressive global brain
damage through local and remote brain tissue damage. More
longitudinal multimodal imaging studies in well characterized
subjects from middle to old age, from different ethnic,
socioeconomic, and clinical backgrounds, are required to fully
understand what influences the varying patterns of WMH and
their associations with cognition, gait, mood, and vulnerability
to stroke. Multimodal imaging is needed to assess parameters
like MD, FA, MTR, T1, perfusion, etc, contemporaneously in
normal and abnormal white and gray matter. Better methods
to measure WMH are needed that are reliable and efficient,
with minimal human input, for large population studies. These
need to be more sophisticated to detect subtleties of WMH,
change over time and response to treatment. These should be
able to detect differences in intensity of WMH, not just size,
and to recognize underlying general changes in brain white
matter with increasing age and by exposure to risk factors.
Better measurement methods are essential for new trials to
test risk factor modification, repurposed drugs, new drugs,
lifestyle modifications, etc, to prevent progressive brain
damage from WMH. Finally, rather than focusing clinical trials
on “Alzheimer’s disease” or “Vascular cognitive impairment”,
clinical diagnoses which likely represent mixtures of pathol-
ogies, perhaps it would be better to focus on intermediary
markers of brain damage, such as WMH, which likely reflect
more specific pathologic mechanisms.
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